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Abstract: Biologic therapy has increasingly been used in the treatment of chronic diseases. 
Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid 
arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of 
these conditions. Since the introduction of anti-TNF agents, there have been many case reports 
of development of malignancy after the initiation of   anti-TNF therapy. With increasing case 
reports, there is growing concern that anti-TNF therapy, albeit useful in the treatment of these 
chronic conditions, might be associated with the development of malignancy in patients. In this 
review we examine the different anti-TNF agents and different studies to evaluate any possible 
association between use of any anti-TNF agent and development of malignancy.
Keywords: tumor necrosis factor inhibitor, malignancy, rheumatoid arthritis, inflammatory 
bowel disease
Introduction
Cytokines are proteins secreted by different types of cells, which in turn act on the 
cells which secrete them (autocrine action) or on surrounding cells (paracrine action) 
or which act systemically away from the local source of secretion (endocrine action). A 
wide array of cytokines is known. Cytokines are critical for many physiologic processes 
including hematopoiesis, immune responses, and inflammation.
Tumor necrosis factor (TNF)-α and -β are both cytokines with pleotropic activity. 
Both play crucial roles in inflammation, are pro-inflammatory, and act on different 
aspects of inflammation like chemotaxis and cytokine production. They are also 
involved in immune regulation. Many different TNF ligands and their respective 
receptors have been identified.
Due to its pivotal role in inflammation and immune response, TNF-α and -β are 
both involved in the pathogenesis of immune diseases such as rheumatoid arthritis 
(RA), Crohn’s disease, asthma, and psoriasis.1 Table 1 lists the diseases which are 
associated with TNF. TNF-α inhibitors have been tried in clinical practice to control 
those diseases and malignancies associated with TNF use in these diseases.
Chronic inflammation is related to carcinogenesis. Chronic inflammation leads 
to chronic cellular proliferation and subsequently has been linked to carcinoma 
development. For example, patients with chronic ulcers are at a risk of development 
of squamous cell carcinoma of the skin. Higher levels of adenocarcinoma of the colon 
have been documented in patients with Crohn’s disease, and RA is also associated with 
an increased incidence of many cancers such as lymphoma and lung cancer.2 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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A healthy immune system is required for the maintenance 
of the genome and prevention of cancer development. 
A healthy immune system is also responsible for detection 
and removal of cancer cells, a process known as immune 
surveillance. Cancer cells which escape destruction by the 
immune system are specific for expressing antigens not 
recognized by the immune system, or for expressing antigens 
which are not detected by the immune system as foreign. 
Cancer cells also have an immunosuppressive effect, thus 
decreasing the ability of the immune system to eliminate 
cancer. The immune system thus contributes to the final 
phenotypic characteristics of tumor, a process known as 
immune editing.3
With this profound role that immunity plays in the 
prevention and final phenotypic characteristic of cancer, 
immune dysfunction helps contribute to the development 
of cancer. With TNF-α playing a pivotal role in immune 
function and inflammation, it has also been associated with 
carcinogenesis. RA, psoriasis, and Crohn’s disease are all 
diseases in which there is immune dysfunction to some 
degree and in which there is a higher risk of carcinogenesis 
compared with the general population. TNF-α is intricately 
involved in immunomodulation. TNF family receptor CD30 
is found on activated B and T lymphocytes, while CD40, 
another TNF family receptor, is found on normal B lym-
phocytes, monocytes, and dendritic cells. These receptors 
and their ligands play a role in every stage of the immune 
response, including priming of antigen presenting cells, 
cytokine release in response to antigens, stimulation and 
activation of helper and cytotoxic T cells, antibody pro-
duction, and class switching of antibodies by B cells. In 
addition, CD30 receptor and CD40 ligand are expressed in 
a number of B and T cell lymphomas and leukemias, and 
high levels of soluble CD30 receptor correlate with poor 
prognosis in patients with anaplastic large-cell lymphoma 
and Hodgkin’s disease.4
Pathophysiology of TNF-α
TNF-α is thus linked to immune response, inflammation, and 
carcinogenesis, although in some studies it has been shown 
to be associated with antitumor activity.7 TNF-α has been 
shown to be pathogenic in development of myeloma directly 
and by induction of interleukin 6, which in turn promotes 
myeloma bone disease and myeloma cell proliferation. On 
the other hand, TNF-α has also been shown to be involved 
in direct cancer cell lysis of leukemia cell lines and it has 
been shown to potentiate the antineoplastic effect of many 
chemotherapeutic agents against leukemia and lymphoma 
cell lines.5–8
TNF-α along with its different ligands, especially 
TRAIL (TNF-related apoptosis-inducing ligand) and 
receptors, is involved in induction of apoptosis through 
interaction with death domain containing proteins, Fas 
associated death domain, and caspases. It can also result in 
inflammation and proliferation of cells via nuclear factor-κB 
(NF-κB) and mitogen-activated protein kinase pathways, 
which are both in turn also associated with carcinogenesis 
There are NF-κB responsive elements in the promotor 
region of many genes involved in carcinogenesis and cell 
cycle progression.9,10
The dual nature of TNF-α activity may be responsible for 
its paradoxical anti- and protumor activities depending on the 
cell, environment, dose, and other factors. TNF-α inhibitors 
are presently used in the treatment of RA, Crohn’s disease, 
ankylosing spondylitis, and psoriasis – diseases which are 
all associated with immune-mediated tissue damage and 
inflammation, all of which are associated with increased risk 
of carcinogenesis. In patients with RA, drugs used to alter the 
course of disease, called disease-modifying drugs, are also 
associated with carcinogenesis; for example, azathioprine 
and cyclophosphamide.11,12 Unequivocal evidence linking 
methotrexate treatment in RA to carcinogenesis, however, 
is lacking.13
Table 1 Diseases in which tumor necrosis factor-α (TNF-α) is implicated, and clinical uses of TNF-α inhibitors
Diseases in which TNF-α is implicated  
in the pathophysiology
TNF-α inhibitors use in clinical practice Reported malignancies associated with  
anti-TNF agent use in these conditions
Rheumatoid arthritis Etanercept, adalimumab Lymphoma, leukemia, solid organ malignancies,  
nonmelanoma skin cancer
Psoriasis Infliximab, etanercept Lymphoma, leukemia, nonmelanoma skin cancer, 
melanoma
Crohn’s disease Infliximab in severe disease  
refractory to other interventions
Lymphoma, leukemia, solid organ malignancies
Ankylosing spondylitis Etanercept, infliximab –
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Clinical experience with TNF-α 
inhibitors and carcinogenesis
There are five different TNF-α inhibitors in clinical use  
at this time:
•	 Etanercept is a dimeric fusion molecule with fusion of 
human immunoglobulin Fc fraction with TNF-α receptor 
gene. It acts by binding TNF-α and making less   available 
for biological activity. It has been used clinically in 
the treatment of RA, psoriasis, psoriatic arthritis, and 
ankylosing spondylitis.
•	 Infliximab is a chimeric mouse/human monoclonal 
antibody against TNF-α clinically used for the treatment 
of Crohn’s disease and ulcerative colitis.
•	 Adalimumab is a completely human monoclonal antibody 
against TNF-α used for treatment of RA.
•	 Certolizumab pegol is the antigen-binding fragment of 
humanized monoclonal anti-TNF antibody bound to 
polyethylene glycol for longer action. It is currently used 
in moderate to severe Crohn’s disease.
•	 Golimumab is a human monoclonal anti-TNF antibody 
used for the treatment of moderate to severe RA, psoriatic 
arthritis, and ankylosing spondylitis.
In a trial to evaluate the efficacy of anti-TNF-α agent 
infliximab in combination with methotrexate in the treatment 
of RA, it was shown that anti-TNF-α antibodies do provide 
long-term relief when used in combination with methotrexate, 
compared with methotrexate alone. There was a significant 
number of patients who developed positive anti-nuclear 
antibodies and anti-double strand DNA after treatment with 
infliximab, indicating that infliximab results in immune 
modification. Five patients developed malignancy after 
starting anti-TNF-α therapy within 30 weeks. This included 
a patient with basal cell carcinoma and another patient with 
moderately differentiated rectal carcinoma. The number of 
cases of cancer development was too low to be significantly 
linked with anti-TNF-α therapy, and was similar to that 
reported by the SEER database.14
With TNF-α being so intricately involved in immune 
response and lymphomas and leukemias, there has been 
concern for development of hematologic malignancies with 
use of TNF-α inhibitor therapy.
There is indeed evidence that TNF-α is associated with 
survival and expansion of multiple myeloma cells in vitro. 
TNF-α was also associated with cutaneous T cell lymphoma 
development. Etanercept was used in trials in patients with 
these two diseases without any significant response. In 
multiple myeloma patients, it actually increased TNF-α 
levels, which might have resulted in poor survival.15,16 
Bupropion, a common antidepressant, was shown to induce 
remission in a patient with Crohn’s disease. The likely 
mechanism of action was thought to be decreased TNF-α 
synthesis by bupropion.17
The risk of development of lymphoma in patients with 
RA increases with the severity of disease.18–20 These findings 
make it hard to elucidate the link between anti-TNF-α therapy 
and development of lymphoma, especially since patients with 
severe RA are treated with anti-TNF-α therapy.
TNF-α and hematologic 
malignancies
Lymphoma has been reported after TNF-α receptor use. Braun 
et al reported 26 cases of lymphoma after treatment with etan-
ercept (18 cases) and infliximab (8 cases) in patients being 
treated for RA and Crohn’s disease. These cases were reported 
to the US Food and Drug Administration as part of the post 
marketing surveillance. These cases developed on average 8 
weeks after initiation of treatment. Two cases of lymphoma 
(one in the etanercept group and one in the infliximab group) 
resolved after stopping anti-TNF-α treatment, without the 
need for any other therapy. The age-adjusted incidence of 
lymphoma during this time (1992–1998) was 18.3/100,000. 
As the exact number of patients taking these medications 
was not known, and due to widespread underreporting of 
these adverse effects, it was difficult to estimate whether this 
represented an increase in the rate of lymphoma or not. One 
of 18 patients who were treated with etanercept developed 
Hodgkin’s lymphoma while three out of eight patients 
who were treated with infliximab developed heart disease. 
The lymphomas were predominantly B cell lymphomas 
(13 out of 18 in etanercept-treated patients and 5 out of 8 in 
infliximab-treated patients), as would be expected for lym-
phoma development after immune suppression.21 There were 
two cases of lymphoma in the group which regressed upon 
stopping of anti-TNF therapy. A similar incidence of develop-
ment of lymphomatoid papulosis (LP) was reported after use 
of infliximab along with azathioprine for treatment of Crohn’s 
disease in a 21-year-old male. He developed cutaneous T cell 
malignancy (LP) 2 years after being on these two antiagents. 
The cutaneous skin lesions resolved in a few months after 
stopping anti-TNF therapy.22
Following this, Wolfe et al reported the standard 
incidence rates (SIR) of development of lymphoma in 
18572 RA patients who they followed prospectively to be 
1.9 (1.3–2.7) for lymphoma development in these patients.  Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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SIR of development of lymphoma after use of anti-TNF-α 
therapy (infliximab or etanercept) was 2.9 (1.7–4.9). SIR 
of development of lymphoma after methotrexate use was 
1.7 (0.9–3.2), indicating that methotrexate use was not 
associated with the development of lymphoma. One of the 
confounding findings in this study was that patients who 
had severe RA, and hence were already at an increased risk 
of lymphoma development, were the ones who received 
anti-TNF-α therapy. This finding makes it difficult to elu-
cidate weather the disease or treatment or its combination 
contribute to the increased incidence of lymphoma in this 
group. This prospective study did not observe the grouping 
of lymphoma cases in the early time period after the start 
of treatment as had been observed in other studies.23
A population-based study undertaken by South Swedish 
Arthritis Treatment Group (SSATG) was reported by Geborek 
et al. They compared 757 patients who received anti-TNF-α 
therapy for RA with an 800-patient population group which 
did not receive this treatment. They followed these patients 
for 5 years from 1997 to 2002 and did not note any increase 
in overall malignancies in the anti-TNF-α group compared 
with the control group. There was an indication of an increase 
in relative risk of lymphoma development in the treatment 
group, but the number of lymphoma cases was too small 
(five in the treatment group, compared with two in the control 
group) to draw any conclusion. The relative risk of lymphoma 
development in patients who received anti-TNF-α therapy 
was 4.9 (0.9–26.2). It is important to note that patients with 
previous cancers were excluded from receiving anti-TNF-α 
treatment. Also the types of lymphomas observed in patients 
treated with anti-TNF-α treatment were predominantly B cell 
lymphomas, similar to that observed in patients with RA, 
lending support to the hypothesis that these lymphomas were 
related to the underlying arthritis rather than its treatment.24,25 
Following this, a meta analysis of 18 studies including 
8808 RA patients by Leombruno did not find an increased 
incidence of lymphoma or any nonhematologic cancer in 
patients treated with anti-TNF therapy. They evaluated studies 
which included treatment with etanercept, infliximab, and 
adalimumab. The information about malignancy was not uni-
formly described in the studies analyzed, and there was con-
cern over under and over reporting of malignancies in some 
included studies. The median follow up of the patients was 
less than 1 year, so the meta analysis could not speculate about 
malignancies which developed after 1 year of follow up.26 We 
reported the development of acute myeloid leukemia (AML) 
in a 57-year-old patient who received etanercept therapy for 
psoriatic arthritis for 6 months. Bone marrow biopsy prior to 
the development of leukemia were not available to confirm 
or exclude myelodysplastic syndrome prior to initiation of 
anti-TNF-α therapy. The patient developed myelodysplastic 
syndrome with acute myeloid leukemia (MDS/AML) which 
was resistant to standard treatments and succumbed to the 
disease. With this and other such case reports of leukemia 
development in patients after anti-TNF-α therapy, we 
recommend routine blood counts and consideration of bone 
marrow biopsy of patients with abnormal blood counts prior 
to initiation of anti-TNF-α therapy to exclude myelodysplasia 
as a predisposing factor to malignancy.27–29
Anti-TNF-α therapy  
and solid tumors
Etanercept use has been associated with the development of 
solid organ malignancies in patients treated for Wegener’s 
granulomatosis. In one study, 6 of 89 patients randomized 
to etanercept treatment in addition to standard therapy 
for Wegener’s granulomatosis (ie, cyclophosphamide) 
developed solid organ malignancies during a median 
follow up of 27 months, compared with no patients who 
received cyclophosphamide alone (P = 0.01). There were 
two cases of colon adenocarcinoma and single cases of 
cholangiocarcinoma, renal cell carcinoma, breast cancer, 
and liposarcoma.30
Infliximab use in patients with inflammatory bowel 
disease has been associated with development of carcinoid 
tumor, signet ring cell carcinoma of the bowel, breast cancer, 
lung cancer, and colorectal cancer.31
It was further shown in another study that 5 of 428 patients 
who received infliximab therapy for methotrexate refractory 
RA developed malignancy within 30 weeks of initiation of 
treatment. The incidence of malignancy in this group was 
similar to that expected of a similar population not treated 
with anti-TNF-α therapy per the SEER database. In another 
study evaluating treatment with infliximab along with metho-
trexate in patients with early RA, 4 of 325 patients developed 
cancer. These included a case of endometrial carcinoma, 
pancreatic carcinoma, colonic adenocarcinoma, and a case 
of AML. This was not higher than the expected rate reported 
by the SEER database.14,32
Adalimumab a fully humanized monoclonal antibody 
against TNF-α and has been used for RA treatment recently. 
Adalimumab treatment in patients refractory to other 
forms of treatment or adalimumab treatment concomitant 
with other antirheumatoid treatment like methotrexate has 
not been shown to increase the rate of lymphomatous or 
nonlymphomatous malignancy over and above that expected Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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in the general population.33,34 However, a recent meta analysis 
of nine trials of anti-TNF-α therapy in RA patients reported 
an increased odds ratio (OR) of development of malignancy 
in patients treated with infliximab or adalimumab, especially 
those treated with higher doses. OR for malignancy develop-
ment was 3.3 (1.2–9.1).35 Though the meta analysis showed 
an increased OR of development of malignancy in patients 
treated with anti-TNF-α therapy, the studies included in 
the analysis had varying duration of follow up and varying 
doses of anti-TNF-α agents. A subsequent large observation 
study done, however, suggested that there was no increase 
in overall malignancies in patients treated with anti-TNF-α 
therapy compared with those not treated with the same in 
RA patients.36 Biancone et al evaluated the development of 
new cancers in 404 patients with Crohn’s disease who were 
treated with infliximab and compared them to a group of 
404 patients with Crohn’s disease who did not receive inf-
liximab for a period of 5 years and did not find an increase 
in the incidence of malignancy in the group treated with 
infliximab.37 A similar result was obtained by Lichtenstein 
et al in evaluating infliximab therapy for CD patients. They 
followed 6273 patients with CD for 15000 patient years in the 
TREAT registry and did not find an increase in the incidence 
of malignancy in the infliximab-treated group.38
Lees et al evaluated the safety of anti-TNF therapy in 
patients with Crohn’s disease and ulcerative colitis. They 
evaluated 202 patients with median follow up of 2.4 years. 
They noted three cases of hematological malignancy and 
three cases of bronchogenic carcinoma.39
There have been recent studies suggestive of increased 
incidence of lung cancer in elderly smokers and patients 
with chronic obstructive pulmonary disease (COPD).40,41 Two 
elderly smokers developed infliximab-related lung cancer 
in a Mayo clinic trial of 500 patients with Crohn’s disease.40 
Of the 157 patients in the infliximab group, in patients with 
COPD, there were nine cases of malignancy development 
compared with 1 of 77 patients in the control group. Of the 
nine cases of malignancy in the treatment group, four were 
lung cancers.41
There has been a case report of non small cell lung can-
cer development in a patient who received infliximab and 
later adalimumab. The tumor was positive for TNF 1 and 2 
receptors. It regressed and stayed in remission after discon-
tinuing anti-TNF therapy.42
Certolizumab Pegol has shown efficacy in patients 
with Crohn’s disease who are infliximab-naïve and also in 
those who have been treated with infliximab before.43 In a 
placebo-controlled double-blind trial of 662 patients with 
Crohn’s disease, certolizumab did not increase the incidence 
of malignancy compared with placebo.44
Golimumab, a human monoclonal anti-TNF antibody, 
has shown efficacy in patients with RA who had previously 
been treated with other anti-TNF agents. A systemic review 
of a study including 1231 patients who were treated with 
golimumab and 483 control patients did not find any 
difference in the rates of malignancy in both groups.45 
Another study noted a nonsignificant increase in the rates 
of overall malignancy and basal cell carcinoma in patients 
treated with golimumab in combination with disease-
modifying antirheumatic drugs (DMARD) (891 patients) 
when compared with placebo alone (666 patients). Though 
the results of this meta analysis are not statistically signifi-
cant, the trend towards increased malignancy and basal cell 
carcinoma should be kept in mind when using golimumab 
in combination with DMARDs.46
Anti-TNF-α therapy  
and skin cancer
Anti-TNF-α therapy has been associated with melanoma and 
nonmelanotic skin cancers (SCC and BCC) though no study 
to date has conclusively proved the increased incidence of 
either of these with use of anti-TNF-α therapy in patients. 
There have been incidences of development of acute kera-
toacanthomas and SCC in patients who are treated with anti-
TNF-α therapy. The short time of development of these SCC 
and keratoacanthoma again point toward the de-repression of 
latent malignancy as the potential mechanism of neoplasm 
potentiation.47,48
Lebwohl et al studied 1442 patients who received 
etanercept for RA and followed them for 5 years and did not 
find an increased incidence of squamous cell carcinoma in 
these patients (4 cases over 5 years) compared to the general 
population (13.9 cases in Arizona and 5.9 n Minnesota). This 
and another study by Burge did not support the association of 
anti-TNF-α therapy with nonmelanotic skin cancer.49,50
A multivariate Cox proportional hazard analysis of 
rheumatoid and osteoarthritis patients indicated that 
prednisone use and concomitant use of anti-TNF-α therapy 
and methotrexate were significantly associated with the 
development of nonmelanotic skin cancers, ie, SCC and BCC. 
Multiple fields of data are missing from the study, including 
confirmed diagnosis of patients as having osteoarthritis or 
RA, lack of family history, and past history of skin cancers. 
The duration and doses of anti-TNF-α agents used were 
also not available. These restrictions and the observational 
nature, does not support the strong association of anti-TNF-α  Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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therapy with skin cancer.51 A recent large observational 
study of 13,001 patients, however, did report an increased 
OR of development of nonmelanotic skin cancer in patients 
who received anti-TNF-α therapy (OR of 1.5 with 95% 
confidence interval 1.2–1.8; P value , 0.001), but did not 
report any increase in the OR of development of any other 
malignancy.36
Contraindications to use  
of anti-TNF agents
Other instances of development of carcinomas within a short 
time of anti-TNF-α therapy indicate a potential derepression 
of occult malignancy as a potential method of development 
of carcinoma. An occult malignancy which was hitherto in 
check by the immune system, developed into a full blown 
cancer by the immune modification brought about by anti-
TNF-α therapy. With this in mind, the British Society of 
Rheumatology recommends exercising caution while pre-
scribing anti-TNF-α drugs to patients with prior malignancy 
or premalignant conditions like Barrett’s esophagus, cervical 
dysplasia, and large bowel polyps. Myelodysplastic syndrome 
should be added to this list as it is a premalignant condition 
more common in the elderly, increasing in incidence, and 
associated with leukemia. However, these inhibitors may be 
used more safely if the patient has not had any recurrence of 
cancer for 10 years.52 The American College of Rheumatology 
contraindicates the use of anti-TNF agents in patients who 
had a lymphoid malignancy in the last 5 years.53
Conclusion
Anti-TNF-α inhibitors are potent drugs and have 
theoretical and real risks in terms of decreasing tumor 
surveillance and allowing cancer cells to grow and pro-
liferate. Clinical trials have shown that there is a higher 
than expected rate of lymphoid malignancies after TNF-α, 
but probably not higher than expected for solid tumors. 
Whether the higher than expected cancer rates are solely 
due to drugs or to underlying conditions or genetic pre-
dispositions giving rise to the underlying disease and the 
subsequent cancer is not known. More studies may help 
to elucidate the link between TNF-α inhibitors and cancer 
risk. In the meantime, caution should be used in treating 
patients with active or prior cancer, or those with high risk 
for developing cancer.
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